Paraoxonase 192 gene polymorphism and serum paraoxonase activity in high grade gliomas and meningiomas

Cell Biochemistry and Function

Volumn 24, Issue 5, 2006, Pages 455-460

  Kafadar, Ali Metin ^a   Ergen, Arzu ^a   Zeybek, Umit ^a   Agachan, Bedia ^a   Kuday, Cengiz ^a   Isbir, Turgay ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Glioma; Lipid peroxidation; Meningioma; Paraoxonase; Polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; PARAOXONASE 192 ENZYME; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENOTYPE; GLIOMA; HUMAN; MALE; MENINGIOMA; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ARYLDIALKYLPHOSPHATASE; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; GLIOMA; HUMANS; LIPID PEROXIDATION; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 33748620667     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1284     Document Type: Article

References (28)

1. Lim M, Harsh GR IV. Neuro-oncology: An Overview. In Principles of Neurosurgery, Rengachary SS, Ellenbogen RG (eds). Elsevier Mosby: London, 2005; 429-449.
2. Walker AE, Robins M, Weinfeld FD. Epidemiology of brain tumours: the national survey of intracranial neoplasms. Neurology 1985; 35: 219-226.
3. Holland EC. The molecular genetics of intracranial gliomas. In Textbook of Neurological Surgery, Batjer HH, Loftus CM (eds). Lippincott Williams & Wilkins: Philadelphia, 2003; 1229-1240.
4. Ames BN. Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science 1983; 221: 1256-1264.
5. Goldstein BD, Witz G. Free radicals and carcinogenesis. Free Radic Res Commun 1990; 11: 3-10.
6. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 1993; 3: 73-76.
7. Marchesani M, Hakkarainen A, Tuomainen TK, et al. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish Men. J Natl Cancer Inst 2003; 95: 812-818.
8. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genet 1996; 14: 334-336.
9. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986; 32: 671-673.
10. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-199.
11. Akcay MN, Yilmaz I, Polat MF, Akcay G. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 2003; 50(Suppl. 2): 273-275.
12. Akcay MN, Polat MF, Yilmaz I, Akcay G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003; 50(Suppl. 2): 250-252.
13. Weber WW. Influence of heredity on human sensitivity to environmental chemicals. Environ Mol Mutagen 1995; 25(Suppl. 26): 102-114.
14. Garin MC, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentration of the enzyme: a possible link between the paraoxonase gene and increased cardiovascular risk in diabetes. J Clin invest 1997; 99: 62-66.
15. Kleihues P, Cavenee WB. 2000. In World Health Organization Classification of Tumors: Pathology and Genetics: Tumors of the nervous system. IARC Press: Lyon; 6-7.
16. Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG. Spectrophotometric assay for the enzymatic hydrolysis of the active metabolites of chlorpyrites and parathion by plasma paraoxonase/arylesterase. Anal Biochem 1989; 180: 242-247.
17. Miller SA, Dykes DD, Polesky HS. Simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988; 16: 1215.
18. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598-608.
19. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104: 129-135.
20. Kokoglu E, Belce A, Ozyurt E, Tepeler Z. Xanthine oxidase concentrations in human brain tumors. Cancer Lett 1990; 50: 179-181.
21. Ikeda Y, Long DM. Oxygen free radicals in the genesis of peritumoural brain oedema in experimental malignant brain tumours. Acta Neurochir 1990; 51(Suppl. Wien): 142-144.
22. Pu PY, Lan J, Shan SB, et al. Study of the antioxidant enzymes in human brain tumors. J Neurooncol 1996; 29: 121-128.
23. Cirak B, Inci S, Palaoglu S, Bertan V. Lipid peroxidation in cerebral tumors. Clin Chim Acta 2003; 327: 103-107.
24. Rao GM, Rao AV, Raja A, Rao S, Rao A. Lipid peroxidation in brain tumors. Clin Chim Acta 2000; 302: 205-211.
25. Voetsch B, Benke KS, Damasceno BP, Siqueira LH, Loscalzo J. Paraoxonase 192 Gln/Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 2002; 33: 1459-1464.
26. Rojas-Garcia AE, Solis-Heredia MJ, Pina-Guzman B, Vega L, Lopez-Carrillo L, Quintanilla-Vega B. Genetic polymorphism and activity of PON1 in a Mexican population. Toxicol Appl Pharmacol 2005; 205: 282-289.
27. Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 2002; 118: 477-481.
28. Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005; 63: 240-251.